How to buy Rafael Holdings Inc Class B stock (RFL)

Rafael Holdings Inc Class B is a real estate services business based in the US. Rafael Holdings Inc Class B shares (RFL) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $1.80 – a decrease of 4.26% over the previous week.

Our top picks for where to buy Rafael Holdings Inc Class B stock

Buy Rafael Holdings Inc Class B stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Rafael Holdings Inc Class B stock price (NYSE: RFL)

Use our graph to track the performance of RFL stocks over time.

Rafael Holdings Inc Class B shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$1.80
52-week range	$1.29 - $2.50
50-day moving average more info button	$1.92
200-day moving average more info button	$1.67
Wall St. target price	N/A
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.67

Is it a good time to buy Rafael Holdings Inc Class B stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Rafael Holdings Inc Class B price performance over time

Historical closes compared with the close of $1.8 from 2024-12-19

1 week (2024-12-13)	-4.26%
1 month (2024-11-21)	-11.33%
3 months (2024-09-20)	4.65%
6 months (2024-06-21)	25.87%

1 year (2023-12-21)	-1.10%
2 years (2022-12-21)	1.12%
3 years (2021-12-21)	5.32
5 years (2019-12-20)	17.35

Rafael Holdings Inc Class B financials

Revenue TTM	$637,000
Gross profit TTM	$279,000
Return on assets TTM	-65.56%
Return on equity TTM	-71.09%
Profit margin	0%
Book value	$3.34
Market Capitalization more info button	$50.9 million

TTM: trailing 12 months

Rafael Holdings Inc Class B share dividends

We're not expecting Rafael Holdings Inc Class B to pay a dividend over the next 12 months.

Rafael Holdings Inc Class B share price volatility

Over the last 12 months, Rafael Holdings Inc Class B's shares have ranged in value from as little as $1.29 up to $2.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Rafael Holdings Inc Class B's is 1.073. This would suggest that Rafael Holdings Inc Class B's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Rafael Holdings Inc Class B overview

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), a stable analog of transient, acylated catalytic intermediates of lipoate currently under phase 2 open-label multi-cohort study evaluating CPI-613 in combination with hydroxychloroquine and 5-fluorouracil or gemcitabine in patients with advanced chemorefractory colorectal, pancreatic, or other solid cancers; and under phase 1 dose-escalation study of CPI-613 in combination with chemoradiation in patients with pancreatic adenocarcinoma. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome.

Frequently asked questions

What percentage of Rafael Holdings Inc Class B is owned by insiders or institutions?
Currently 20.766% of Rafael Holdings Inc Class B shares are held by insiders and 10.158% by institutions. When does the fiscal year end for Rafael Holdings Inc Class B?
Rafael Holdings Inc Class B's fiscal year ends in July. Where is Rafael Holdings Inc Class B based?
Rafael Holdings Inc Class B's address is: 520 Broad Street, Newark, NJ, United States, 07102 What is Rafael Holdings Inc Class B's ISIN number?
Rafael Holdings Inc Class B's international securities identification number is: US75062E1064 What is Rafael Holdings Inc Class B's CUSIP number?
Rafael Holdings Inc Class B's Committee on Uniform Securities Identification Procedures number is: 75062E106